What can we learn from molecular dynamics simulations for GPCR drug design?

Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R).

[1]  T. Williams,et al.  Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation* , 2007, Journal of Biological Chemistry.

[2]  Wim F Vranken,et al.  ACPYPE - AnteChamber PYthon Parser interfacE , 2012, BMC Research Notes.

[3]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[4]  Alan Wise,et al.  Target validation of G-protein coupled receptors. , 2002, Drug discovery today.

[5]  Kenneth Lundstrom,et al.  An Overview on GPCRs and Drug Discovery: Structure-Based Drug Design and Structural Biology on GPCRs , 2009, Methods in molecular biology.

[6]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[7]  G. Keserű,et al.  Fragment-based lead discovery on G-protein-coupled receptors , 2013, Expert opinion on drug discovery.

[8]  Thomas Fox,et al.  Accuracy Assessment and Automation of Free Energy Calculations for Drug Design , 2014, J. Chem. Inf. Model..

[9]  Vijay S. Pande,et al.  Everything you wanted to know about Markov State Models but were afraid to ask. , 2010, Methods.

[10]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[11]  Wilfred F van Gunsteren,et al.  Practical Aspects of Free-Energy Calculations: A Review. , 2014, Journal of chemical theory and computation.

[12]  Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. , 2013, ACS medicinal chemistry letters.

[13]  J. P. Grossman,et al.  Biomolecular simulation: a computational microscope for molecular biology. , 2012, Annual review of biophysics.

[14]  Christofer S Tautermann,et al.  The use of G-protein coupled receptor models in lead optimization. , 2011, Future medicinal chemistry.

[15]  S. Costanzi.  Modeling G protein-coupled receptors and their interactions with ligands. , 2013, Current opinion in structural biology.

[16]  Miles Congreve,et al.  The use of GPCR structures in drug design. , 2011, Advances in pharmacology.

[17]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[18]  O. Civelli,et al.  Orphan G protein‐coupled receptors: targets for new therapeutic interventions , 2004, Annals of medicine.

[19]  Kenneth Lundstrom,et al.  Latest development in drug discovery on G protein-coupled receptors. , 2006, Current protein & peptide science.

[20]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[21]  Frank Noé,et al.  Markov models of molecular kinetics: generation and validation. , 2011, The Journal of chemical physics.

[22]  A. Viola,et al.  Chemokines and their receptors: drug targets in immunity and inflammation. , 2008, Annual review of pharmacology and toxicology.

[23]  H. Hamm,et al.  Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. , 2013, Journal of molecular biology.

[24]  B. Springthorpe,et al.  Chemokine CCR3 antagonists , 2010 .

[25]  Christofer S Tautermann,et al.  GPCR structures in drug design, emerging opportunities with new structures. , 2014, Bioorganic & medicinal chemistry letters.

[26]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[27]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[28]  S. Garland.  Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.

[29]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[30]  Albert C. Pan,et al.  Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.

[31]  J. Mccammon,et al.  Exploring the role of receptor flexibility in structure-based drug discovery. , 2014, Biophysical chemistry.

[32]  Shweta Singh,et al.  Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs. , 2013, Biochimica et biophysica acta.

[33]  Holger Gohlke,et al.  Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.

[34]  Christopher G. Tate,et al.  Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.

[35]  Sid Topiol,et al.  X-ray structural information of GPCRs in drug design: what are the limitations and where do we go? , 2013, Expert opinion on drug discovery.

[36]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[37]  R. Horuk,et al.  I want a new drug: G-protein-coupled receptors in drug development. , 2006, Drug discovery today.

[38]  Alexander D. MacKerell,et al.  Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation , 2009, PLoS Comput. Biol..

[39]  B. Roth,et al.  Tuning up the right signal: chemical and genetic approaches to study GPCR functions. , 2014, Current opinion in cell biology.

[40]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[41]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[42]  M. Harvey,et al.  High-throughput molecular dynamics: the powerful new tool for drug discovery. , 2012, Drug discovery today.

[43]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[44]  G. Hummer,et al.  Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides. , 2009, The journal of physical chemistry. B.

[45]  P. Casarosa,et al.  Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. , 2013, Journal of medicinal chemistry.

[46]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[47]  R. Altman,et al.  Cloud-based simulations on Google Exacycle reveal ligand-modulation of GPCR activation pathways , 2013, Nature chemistry.

[48]  Philip C. Biggin,et al.  Toward an Understanding of Agonist Binding to Human Orexin-1 and Orexin-2 Receptors with G-Protein-Coupled Receptor Modeling and Site-Directed Mutagenesis , 2013, Biochemistry.

[49]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[50]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[51]  Berk Hess,et al.  Improving Efficiency of Large Time-Scale Molecular Dynamics Simulations of Hydrogen-Rich Systems , 1999 .

[52]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[53]  Albert C. Pan,et al.  Activation mechanism of the β2-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.

[54]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[55]  Nagarajan Vaidehi,et al.  First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin. , 2004, Biophysical journal.

[56]  Vadim Cherezov,et al.  Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.

[57]  S. P. Andrews,et al.  Structure‐Based and Fragment‐Based GPCR Drug Discovery , 2014, ChemMedChem.

[58]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[59]  G. Milligan,et al.  Novel Assay Technologies for the Discovery of G Protein-Coupled Receptor Drugs , 2011 .

[60]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[61]  Gregg Siegal,et al.  Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.

[62]  Gabriele Costantino,et al.  Molecular Dynamics Simulations of G Protein‐Coupled Receptors , 2012, Molecular informatics.

[63]  O. Berger,et al.  Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.

[64]  A. Caflisch,et al.  Molecular dynamics in drug design. , 2015, European journal of medicinal chemistry.

[65]  Diane Joseph-McCarthy,et al.  Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..

[66]  Ruben Abagyan,et al.  The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.

[67]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[68]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[69]  Maarten G. Wolf,et al.  g_membed: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation , 2010, J. Comput. Chem..

[70]  Mario Cazzola,et al.  Pharmacology and Therapeutics of Bronchodilators , 2012, Pharmacological Reviews.

[71]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[72]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.

[73]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[74]  Pawel Pasznik,et al.  Towards Improved Quality of GPCR Models by Usage of Multiple Templates and Profile-Profile Comparison , 2013, PloS one.

[75]  Didier Rognan,et al.  A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.

[76]  F. J. Luque,et al.  Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. , 2011, Journal of the American Chemical Society.

[77]  Jan M. Kriegl,et al.  Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model. , 2015, Bioorganic & medicinal chemistry letters.

[78]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[79]  Isabel Beets,et al.  Deorphanizing g protein-coupled receptors by a calcium mobilization assay. , 2011, Methods in molecular biology.